Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > What a week.
View:
Post by Sweeetydi on Feb 15, 2018 8:03pm

What a week.

Reading through this board and am a little shocked that some of TBPs biggest fans have lost faith today with the announcement from SunLife.

As someone who works in HealthCare,  I am constantly making decisions based on evidence based research and best practice. Every meeting I attend,  every policy being implement and every change taking place is done based on evidence based research. 

Physicians are are held accountable for the prescriptions they write today more than they ever were. From my exposure, physicians aren’t just writing off scripts for MJ.  Doctors want research and evidence supporting the drugs they are recommending so that they know their exact mechanisms and side effects.

I think as time goes on that there is going to be a lot more clarification on what makes a product “recreational” versus “medical”.  Insurance companies are not going to shell out money to pay for people to smoke pot which is essentially how the SunLife news is being taken. TBP is still a trailblazer and will be the only reputable product with research supporting it.  Research will pay off for this company.
Comment by Fogcity87 on Feb 15, 2018 8:31pm
I absolutely agree with your point di, the risk in my opinion with the recent development is that physicians may take tetras evidence as developed through their clinical trials and say for example tetra has proven that rxprinceps is effective in reducing nausea and vomiting in cancer patients as evidenced by xyz vs those in the placebo sub group ( you could substitute this example for anything ...more  
Comment by av8tor42 on Feb 15, 2018 8:32pm
Thank you for your post and a thank you for being in one of the hardest professions going...Kudos to you and everyone else in the profession. Cliics are popping up all over the contury where Dr's will prescribe cannabis. You just need a referal. Once a DIN number is established everybody will be on board and from that day on Tetra has nothing...If they where building the pipe like thier news ...more  
Comment by Capitalization on Feb 16, 2018 12:28am
Well said, I have embraced this news and what you speak of is 100% correct.  I haven’t been selling but buying more as I have more cash flow to do so.  The fact that insurance companies are starting to realize the big picture, the better off tetra and it’s practices will pay off.  People also need to think the big picture with the world, Canada is just one small country.  Be ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities